Decreased response to growth hormone after interruption of therapy

Y. Hasegawa, Tomonobu Hasegawa, T. Aso, M. Anzo, S. Kotoh, Y. Tsuchiya

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The relatively high cost of recombinant human growth hormone (rhGH) has raised the issue of whether intermittent treatment regimens might be efficacious for patients with GH deficiency. Two previous reports have suggested that interruption of GH treatment may avoid the typical waning of response associated with continuous GH therapy and may, therefore, result in an advantageous cost-benefit ratio. We have studied 2 patients with GH deficiency treated with rhGH which was interrupted for one month. The one month of interrupted therapy did not have any beneficial effect and may have caused a loss of potential growth. Although our observations are limited, the data indicate that intermittent GH treatment regimens should not be advocated in the absence of additional investigations.

Original languageEnglish
Pages (from-to)7-9
Number of pages3
JournalClinical Pediatric Endocrinology
Volume6
Issue number1
Publication statusPublished - 1997
Externally publishedYes

Fingerprint

Growth Hormone
Human Growth Hormone
Therapeutics
Cost-Benefit Analysis
Costs and Cost Analysis
Growth

Keywords

  • GH
  • GH deficiency
  • GH therapy

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Cite this

Hasegawa, Y., Hasegawa, T., Aso, T., Anzo, M., Kotoh, S., & Tsuchiya, Y. (1997). Decreased response to growth hormone after interruption of therapy. Clinical Pediatric Endocrinology, 6(1), 7-9.

Decreased response to growth hormone after interruption of therapy. / Hasegawa, Y.; Hasegawa, Tomonobu; Aso, T.; Anzo, M.; Kotoh, S.; Tsuchiya, Y.

In: Clinical Pediatric Endocrinology, Vol. 6, No. 1, 1997, p. 7-9.

Research output: Contribution to journalArticle

Hasegawa, Y, Hasegawa, T, Aso, T, Anzo, M, Kotoh, S & Tsuchiya, Y 1997, 'Decreased response to growth hormone after interruption of therapy', Clinical Pediatric Endocrinology, vol. 6, no. 1, pp. 7-9.
Hasegawa, Y. ; Hasegawa, Tomonobu ; Aso, T. ; Anzo, M. ; Kotoh, S. ; Tsuchiya, Y. / Decreased response to growth hormone after interruption of therapy. In: Clinical Pediatric Endocrinology. 1997 ; Vol. 6, No. 1. pp. 7-9.
@article{b7449cda638a48639a13fe760ecaa337,
title = "Decreased response to growth hormone after interruption of therapy",
abstract = "The relatively high cost of recombinant human growth hormone (rhGH) has raised the issue of whether intermittent treatment regimens might be efficacious for patients with GH deficiency. Two previous reports have suggested that interruption of GH treatment may avoid the typical waning of response associated with continuous GH therapy and may, therefore, result in an advantageous cost-benefit ratio. We have studied 2 patients with GH deficiency treated with rhGH which was interrupted for one month. The one month of interrupted therapy did not have any beneficial effect and may have caused a loss of potential growth. Although our observations are limited, the data indicate that intermittent GH treatment regimens should not be advocated in the absence of additional investigations.",
keywords = "GH, GH deficiency, GH therapy",
author = "Y. Hasegawa and Tomonobu Hasegawa and T. Aso and M. Anzo and S. Kotoh and Y. Tsuchiya",
year = "1997",
language = "English",
volume = "6",
pages = "7--9",
journal = "Clinical Pediatric Endocrinology",
issn = "0918-5739",
publisher = "Jeff Corporation Co. Ltd",
number = "1",

}

TY - JOUR

T1 - Decreased response to growth hormone after interruption of therapy

AU - Hasegawa, Y.

AU - Hasegawa, Tomonobu

AU - Aso, T.

AU - Anzo, M.

AU - Kotoh, S.

AU - Tsuchiya, Y.

PY - 1997

Y1 - 1997

N2 - The relatively high cost of recombinant human growth hormone (rhGH) has raised the issue of whether intermittent treatment regimens might be efficacious for patients with GH deficiency. Two previous reports have suggested that interruption of GH treatment may avoid the typical waning of response associated with continuous GH therapy and may, therefore, result in an advantageous cost-benefit ratio. We have studied 2 patients with GH deficiency treated with rhGH which was interrupted for one month. The one month of interrupted therapy did not have any beneficial effect and may have caused a loss of potential growth. Although our observations are limited, the data indicate that intermittent GH treatment regimens should not be advocated in the absence of additional investigations.

AB - The relatively high cost of recombinant human growth hormone (rhGH) has raised the issue of whether intermittent treatment regimens might be efficacious for patients with GH deficiency. Two previous reports have suggested that interruption of GH treatment may avoid the typical waning of response associated with continuous GH therapy and may, therefore, result in an advantageous cost-benefit ratio. We have studied 2 patients with GH deficiency treated with rhGH which was interrupted for one month. The one month of interrupted therapy did not have any beneficial effect and may have caused a loss of potential growth. Although our observations are limited, the data indicate that intermittent GH treatment regimens should not be advocated in the absence of additional investigations.

KW - GH

KW - GH deficiency

KW - GH therapy

UR - http://www.scopus.com/inward/record.url?scp=0031399632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031399632&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 7

EP - 9

JO - Clinical Pediatric Endocrinology

JF - Clinical Pediatric Endocrinology

SN - 0918-5739

IS - 1

ER -